Enhanced expression of FGF19 predicts poor prognosis in patients with non-small cell lung cancer.

ABSTRACT:

Background

Lung cancer is one of the most common cancers and a leading cause of cancer-related death worldwide. Although many treatment options exist for lung cancer, some patients still suffer postoperative recurrence, and a consequent reduction of overall survival (OS). Our study aimed to investigate the correlation of FGF19 expression with the clinicopathological features and survival outcomes of non-small cell lung cancer (NSCLC) patients.

Methods

Bioinformatics analysis was conducted using the data from The Cancer Genome Atlas (TCGA) database to distinguish between the FGF19 levels of tumor and normal tissue and to determine their correlation with the OS. A total of 187 NSCLC patients who underwent radical resection of lung cancer were enrolled, and tissues were collect

SUBMITTER: Chen J 

PROVIDER: S-EPMC8024864 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature